Premium
Vemurafenib‐induced interface dermatitis manifesting as radiation‐recall and a keratosis pilaris‐like eruption
Author(s) -
Braunstein Inbal,
Gangadhar Tara C.,
Elenitsas Rosalie,
Chu Emily Y.
Publication year - 2014
Publication title -
journal of cutaneous pathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 75
eISSN - 1600-0560
pISSN - 0303-6987
DOI - 10.1111/cup.12318
Subject(s) - vemurafenib , medicine , dermatology , cancer research , v600e , keratosis , mapk/erk pathway , actinic keratosis , kinase , protein kinase a , melanoma , mutation , pathology , metastatic melanoma , biology , genetics , gene , basal cell
Vemurafenib is a specific inhibitor of the V600E mutated BRAF protein kinase used for the treatment of unresectable or metastatic melanoma harboring this mutation. Multiple predictable side effects have been described with use of this targeted therapy, and implicate BRAF and mitogen activated protein kinase ( MAPK ) signaling pathways in their pathogenesis. Herein, we report the novel finding of an interface dermatitis in radiation recall and a keratosis pilaris‐like clinical reaction in a patient treated with vemurafenib.